Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii : a systematic review and meta-analysis
Open Access
- 2 February 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (3)
Abstract
Background: Emergence and spread of carbapenem-resistant Acinetobacter baumannii (CRAB) producing metallo-β-lactamases (MBLs), especially New Delhi MBLs (NDMs), are concerning due to resistance to last-resort antibiotics. Methods: PubMed and Scopus were queried for studies published between 2020 and 2024 reporting MBL prevalence in CRAB isolates. Risk of bias was assessed across the population, setting and measurement domains. Binomial-Normal mixed-effects models were applied to estimate regional and country-specific weighted MBL and NDM prevalence proportions in CRAB. Subgroup and meta-regression analyses were performed to investigate heterogeneity. Results: Two hundred thirty-three studies reporting 58 676 CRAB isolates were analysed. The global MBL prevalence in CRAB was 5.3% [95% confidence interval CI), 3.3%–8.2%]. Regional variability explained a substantial portion of heterogeneity in meta-regression (R2 = 35%). MBL prevalence in CRAB was highest in the Eastern Mediterranean (42.1%; 95% CI, 28.7%–56.8%) and African (36.1%; 95% CI, 12.2%–69.8%) regions, moderately high in South-East Asia (17.9%; 95% CI, 9.6%–30.9%), and low (<1%) in Europe, the Americas and the Western Pacific region. MBL prevalence in CRAB was higher in studies conducted during 2020–2024 than during 2012–2019 (7.2% versus 4.2%; adjusted odds ratio 2.3, P = 0.024). NDM was the dominant MBL in CRAB, with a global prevalence of 1.7% (95% CI, 1.1%–2.7%) in 218 studies. Conclusions: Although its global prevalence is low, MBL-producing CRAB is common in specific regions and countries, threatening the utility of new antibiotics. Sustained surveillance, rigorous infection control and antimicrobial stewardship are required to preserve the activity of last-resort antimicrobials.Keywords
This publication has 46 references indexed in Scilit:
- Are cefiderocol or sulbactam/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature reviewInfection, 2025
- Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: a 5-year cohort study in intensive care patientsClinical Microbiology and Infection, 2025
- Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysisClinical Microbiology and Infection, 2023
- In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020–2021: a multicenter studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2023
- Meta‐analysis of prevalence: I2 statistic and how to deal with heterogeneityResearch Synthesis Methods, 2022
- In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerationsInfection, 2022
- Quality assessment of prevalence studies: a systematic reviewJournal of Clinical Epidemiology, 2020
- Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenemsInfection, 2020
- Carbapenem-resistant Acinetobacter baumannii in patients with burn injury: A systematic review and meta-analysisBurns, 2019
- Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse dataStatistics in Medicine, 2010